{
  "id": "gillmore_staging_attr_cm",
  "title": "Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",
  "description": "Staging system for transthyretin amyloid cardiomyopathy using NT-proBNP and estimated glomerular filtration rate (eGFR) to stratify patients into prognostic categories for both wild-type and variant ATTR-CM",
  "category": "cardiology",
  "version": "2018",
  "parameters": [
    {
      "name": "nt_probnp",
      "type": "float",
      "required": true,
      "description": "N-terminal pro-B-type natriuretic peptide (NT-proBNP) level",
      "validation": {
        "min": 0,
        "max": 50000
      },
      "unit": "ng/L"
    },
    {
      "name": "egfr",
      "type": "float", 
      "required": true,
      "description": "Estimated glomerular filtration rate (eGFR)",
      "validation": {
        "min": 5,
        "max": 150
      },
      "unit": "ml/min"
    }
  ],
  "result": {
    "name": "gillmore_stage",
    "type": "string",
    "unit": "stage",
    "description": "Gillmore staging for ATTR-CM prognosis (Stage I, II, or III)"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 1,
        "max": 1,
        "stage": "Stage I",
        "description": "Best prognosis",
        "interpretation": "NT-proBNP ≤3000 ng/L and eGFR ≥45 ml/min. Median survival 69.2 months. Best prognostic category with lowest mortality risk."
      },
      {
        "min": 2,
        "max": 2,
        "stage": "Stage II",
        "description": "Intermediate prognosis",
        "interpretation": "Intermediate biomarker profile not meeting Stage I or III criteria. Median survival 46.7 months. Intermediate prognostic category."
      },
      {
        "min": 3,
        "max": 3,
        "stage": "Stage III",
        "description": "Worst prognosis",
        "interpretation": "NT-proBNP >3000 ng/L and eGFR <45 ml/min. Median survival 24.1 months. Highest mortality risk requiring intensive management."
      }
    ]
  },
  "references": [
    "Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.",
    "Fontana M, Corovic A, Scully P, Moon JC. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging. 2019;12(11 Pt 2):2345-2356. doi: 10.1016/j.jcmg.2019.06.023.",
    "Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014-1020. doi: 10.1016/j.jacc.2016.06.033."
  ],
  "formula": "Stage I: NT-proBNP ≤3000 ng/L AND eGFR ≥45 ml/min; Stage III: NT-proBNP >3000 ng/L AND eGFR <45 ml/min; Stage II: All other combinations",
  "notes": [
    "Developed by the UK National Amyloidosis Centre for both wild-type and variant ATTR-CM",
    "Based on 869 patients with cardiac ATTR amyloidosis (553 wild-type, 316 variant)",
    "Validated in a separate cohort of 318 patients",
    "Uses readily available biomarkers (NT-proBNP and eGFR)",
    "Stage I patients: 393 (45%) with median survival 69.2 months",
    "Stage II patients: 334 (38%) with median survival 46.7 months", 
    "Stage III patients: 142 (16%) with median survival 24.1 months",
    "Hazard ratios compared to Stage I: Stage II HR 2.05 (95% CI 1.54-2.72), Stage III HR 3.80 (95% CI 2.73-5.28)",
    "Useful for clinical decision-making and trial design",
    "Should be used in conjunction with comprehensive clinical evaluation",
    "Regular monitoring of biomarkers recommended for disease progression assessment"
  ]
}